PL2575878T3 - Szczepionki zawierające cholesterol i CPG jako jedyne cząsteczki adiuwantowo-nośnikowe - Google Patents

Szczepionki zawierające cholesterol i CPG jako jedyne cząsteczki adiuwantowo-nośnikowe

Info

Publication number: PL2575878T3
Authority: PL; Poland
Prior art keywords: cpg; vaccines; cholesterol; carrier molecules; sole adjuvant
Prior art date: 2010-05-28

Application number

PL11727536T

Other languages

English (en)

Inventor

Heather Lynn Davis

Paul Joseph Dominowski

Risini Dhammika Weeratna

Original Assignee

Zoetis Belgium S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-28

Filing date

2011-05-27

Publication date

2018-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44626939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2575878(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-27 Application filed by Zoetis Belgium S.A. filed Critical Zoetis Belgium S.A.

2018-12-31 Publication of PL2575878T3 publication Critical patent/PL2575878T3/pl

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
235000012000 cholesterol Nutrition 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Virology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

PL11727536T 2010-05-28 2011-05-27 Szczepionki zawierające cholesterol i CPG jako jedyne cząsteczki adiuwantowo-nośnikowe PL2575878T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US34924410P	2010-05-28	2010-05-28
PCT/IB2011/052347 WO2011148356A1 (en)	2010-05-28	2011-05-27	Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
EP11727536.2A EP2575878B1 (en)	2010-05-28	2011-05-27	Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules

Publications (1)

Publication Number	Publication Date
PL2575878T3 true PL2575878T3 (pl)	2018-12-31

Family

ID=44626939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11727536T PL2575878T3 (pl)	2010-05-28	2011-05-27	Szczepionki zawierające cholesterol i CPG jako jedyne cząsteczki adiuwantowo-nośnikowe

Country Status (22)

Country	Link
US (1)	US10456463B2 (pl)
EP (1)	EP2575878B1 (pl)
JP (3)	JP6034285B2 (pl)
KR (1)	KR101528021B1 (pl)
CN (1)	CN103025351B (pl)
AU (2)	AU2011259718B2 (pl)
BR (1)	BR112012030337B1 (pl)
CA (1)	CA2800158C (pl)
CL (1)	CL2012003299A1 (pl)
DK (1)	DK2575878T3 (pl)
ES (1)	ES2683316T3 (pl)
HR (1)	HRP20181039T1 (pl)
HU (1)	HUE038894T2 (pl)
LT (1)	LT2575878T (pl)
MX (1)	MX347471B (pl)
NZ (1)	NZ603527A (pl)
PL (1)	PL2575878T3 (pl)
PT (1)	PT2575878T (pl)
RS (1)	RS57428B1 (pl)
SI (1)	SI2575878T1 (pl)
WO (1)	WO2011148356A1 (pl)
ZA (1)	ZA201208837B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2759306T1 (sl) *	2008-12-09	2016-05-31	Coley Pharmaceutical Group, Inc.	Imunostimulacijski oligonukleotidi
US8980279B2 (en) *	2010-07-26	2015-03-17	Qu Biologics	Personalized site-specific immunomodulation
US9314519B2 (en) *	2012-08-21	2016-04-19	Intervet Inc.	Liquid stable virus vaccines
SI3542819T1 (sl) *	2013-05-14	2021-11-30	Zoetis Services Llc	Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
EP3024936B1 (en)	2013-07-25	2019-09-04	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
UA130246C2 (uk) *	2013-09-19	2025-12-31	Зоетіс Сервісіз Ллс	Ад'ювант на основі олії
MX2016004961A (es)	2013-10-17	2016-06-28	Zoetis Services Llc	Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
EP4241853B1 (en) *	2013-11-26	2026-02-11	Zoetis Services LLC	Compositions for induction of immune response
TR201908550T4 (tr)	2014-06-04	2019-07-22	Exicure Inc	Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
CN115317600A (zh) *	2015-01-16	2022-11-11	硕腾服务有限责任公司	口蹄疫疫苗
EP3325015B1 (en) *	2015-07-20	2021-05-12	Zoetis Services LLC	Liposomal adjuvant compositions
US10456459B2 (en) *	2015-07-20	2019-10-29	Zoetis Services Llc	Liposomal adjuvant compositions
JP7076798B2 (ja)	2015-09-09	2022-05-30	清華大学	効果的なワクチンアジュバントとするメバロン酸経路の阻害剤
CN107149671B (zh) *	2016-03-03	2021-02-05	郭文江	一种药物组合物及其应用
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018119142A1 (en)	2016-12-21	2018-06-28	Amgen Inc.	Anti-tnf alpha antibody formulations
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
CR20200260A (es) *	2017-12-15	2020-08-01	Bayer Animal Health Gmbh	Composiciones inmunoestimulantes
CN114514238A (zh) *	2019-07-12	2022-05-17	研究发展基金会	埃立克体疫苗和免疫原性组合物
TWI884296B (zh) *	2020-08-11	2025-05-21	美商碩騰服務公司	抗冠狀病毒疫苗
IT202100014747A1 (it) *	2021-06-07	2022-12-07	Consiglio Nazionale Ricerche	Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CN115645417A (zh) *	2022-10-17	2023-01-31	武汉轻工大学	鹅去氧胆酸在制备治疗或预防猪病毒性腹泻的药物或饲料添加剂中的应用
CN118059219B (zh) *	2024-04-19	2024-06-25	西南交通大学	一种肥胖相关乳腺癌的个性化核酸疫苗及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (de)	1981-10-23	1992-06-04	Molecular Biosystems Inc	Oligonukleotides heilmittel und dessen herstellungsverfahren.
DE4321946A1 (de)	1993-07-01	1995-01-12	Hoechst Ag	Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP1167379A3 (en) *	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
GB9718901D0 (en) *	1997-09-05	1997-11-12	Smithkline Beecham Biolog	Vaccine
PT1104306E (pt)	1998-08-10	2006-05-31	Antigenics Inc	Composicoes de cpg e adjuvantes de saponina e seus metodos
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
GB9921146D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
AU783118B2 (en)	1999-09-27	2005-09-29	Coley Pharmaceutical Gmbh	Methods related to immunostimulatory nucleic acid-induced interferon
CN1301572A (zh) *	1999-10-28	2001-07-04	上海生物制品研究所	用于疫苗的佐剂组合物
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
ATE411054T1 (de)	2001-08-17	2008-10-15	Coley Pharm Gmbh	Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
GB0123580D0 (en)	2001-10-01	2001-11-21	Glaxosmithkline Biolog Sa	Vaccine
JP4658475B2 (ja) *	2001-11-07	2011-03-23	サイトスバイオテクノロジーアーゲー	骨疾患治療用の抗原アレイ
WO2003066649A1 (en) *	2002-02-04	2003-08-14	Biomira Inc.	Immunostimulatory, covalently lipidated oligonucleotides
CN100471486C (zh) *	2002-08-12	2009-03-25	戴纳伐克斯技术股份有限公司	免疫调节组合物,其制备方法和使用方法
BRPI0410423A (pt) *	2003-05-07	2006-06-06	Sanofi Pasteur Inc	processo de imunogenicidade melhorada para vacinação meningocócica
MXPA06001996A (es) *	2003-08-28	2006-06-20	Immune Response Corp Inc	Composiciones de hiv inmunogeneticas y metodos relacionados.
GB0323965D0 (en) *	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
US20050175630A1 (en) *	2003-12-23	2005-08-11	Eyal Raz	Immunogenic compositions and methods of use thereof
JP5600375B2 (ja) *	2004-03-09	2014-10-01	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	インフルエンザウイルスワクチン
CN101217973A (zh) *	2004-03-12	2008-07-09	海布里顿公司	使用第二代免疫调节寡核苷酸增强的hiv疫苗活性
EP1776105A2 (en) *	2004-07-18	2007-04-25	Coley Pharmaceutical Group, Ltd	Methods and compositions for inducing innate immune responses
WO2006056142A1 (en) *	2004-11-29	2006-06-01	Changchun Huapu Biotechnology Co., Ltd.	Cpg single-strand deoxynucleotides for use as adjuvant
EP1849780A1 (en) *	2006-04-21	2007-10-31	De Staat der Nederlanden, vert. door de minister van VWS	Vaccine against nicotine addiction
CN101460620B (zh) *	2006-05-31	2012-02-15	东丽株式会社	免疫刺激寡核苷酸及其药物用途
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
CA2687441A1 (en) *	2007-05-17	2008-11-27	Coley Pharmaceutical Group, Inc.	Class a oligonucleotides with immunostimulatory potency
CA2710983A1 (en) *	2007-12-27	2009-10-01	The Ohio State University Research Foundation	Lipid nanoparticle compositions and methods of making and using the same
ES2569907T3 (es)	2008-06-27	2016-05-13	Zoetis Services Llc	Composiciones adyuvantes novedosas

2011
- 2011-05-27 EP EP11727536.2A patent/EP2575878B1/en active Active
- 2011-05-27 DK DK11727536.2T patent/DK2575878T3/en active
- 2011-05-27 LT LTEP11727536.2T patent/LT2575878T/lt unknown
- 2011-05-27 AU AU2011259718A patent/AU2011259718B2/en active Active
- 2011-05-27 JP JP2013513022A patent/JP6034285B2/ja active Active
- 2011-05-27 NZ NZ603527A patent/NZ603527A/en unknown
- 2011-05-27 US US13/699,997 patent/US10456463B2/en active Active
- 2011-05-27 RS RS20180784A patent/RS57428B1/sr unknown
- 2011-05-27 PL PL11727536T patent/PL2575878T3/pl unknown
- 2011-05-27 PT PT11727536T patent/PT2575878T/pt unknown
- 2011-05-27 SI SI201131538T patent/SI2575878T1/sl unknown
- 2011-05-27 BR BR112012030337-6A patent/BR112012030337B1/pt active IP Right Grant
- 2011-05-27 CN CN201180036906.3A patent/CN103025351B/zh active Active
- 2011-05-27 HR HRP20181039TT patent/HRP20181039T1/hr unknown
- 2011-05-27 MX MX2012013731A patent/MX347471B/es active IP Right Grant
- 2011-05-27 JP JP2011118735A patent/JP2011251963A/ja not_active Withdrawn
- 2011-05-27 WO PCT/IB2011/052347 patent/WO2011148356A1/en not_active Ceased
- 2011-05-27 CA CA2800158A patent/CA2800158C/en active Active
- 2011-05-27 KR KR1020127033947A patent/KR101528021B1/ko active Active
- 2011-05-27 HU HUE11727536A patent/HUE038894T2/hu unknown
- 2011-05-27 ES ES11727536.2T patent/ES2683316T3/es active Active
2012
- 2012-11-22 ZA ZA2012/08837A patent/ZA201208837B/en unknown
- 2012-11-26 CL CL2012003299A patent/CL2012003299A1/es unknown
2016
- 2016-05-31 AU AU2016203611A patent/AU2016203611B2/en active Active
- 2016-09-06 JP JP2016173482A patent/JP6133482B2/ja active Active

Also Published As

Publication number	Publication date
US20130084306A1 (en)	2013-04-04
EP2575878A1 (en)	2013-04-10
BR112012030337A2 (pt)	2017-01-24
MX347471B (es)	2017-04-24
HUE038894T2 (hu)	2018-12-28
CL2012003299A1 (es)	2013-03-08
LT2575878T (lt)	2018-11-12
CA2800158A1 (en)	2011-12-01
AU2016203611B2 (en)	2017-06-15
ZA201208837B (en)	2013-08-28
HRP20181039T1 (hr)	2018-08-24
PT2575878T (pt)	2018-10-03
EP2575878B1 (en)	2018-06-13
JP2017048187A (ja)	2017-03-09
NZ603527A (en)	2014-10-31
KR101528021B1 (ko)	2015-06-10
DK2575878T3 (en)	2018-08-13
JP2011251963A (ja)	2011-12-15
AU2016203611A1 (en)	2016-06-16
CA2800158C (en)	2020-07-21
SI2575878T1 (sl)	2018-12-31
AU2011259718A1 (en)	2012-12-06
RS57428B1 (sr)	2018-09-28
MX2012013731A (es)	2013-12-16
WO2011148356A1 (en)	2011-12-01
CN103025351A (zh)	2013-04-03
BR112012030337B1 (pt)	2021-04-27
AU2011259718B2 (en)	2016-03-03
JP6034285B2 (ja)	2016-11-30
CN103025351B (zh)	2016-08-24
JP6133482B2 (ja)	2017-05-24
JP2013532140A (ja)	2013-08-15
US10456463B2 (en)	2019-10-29
KR20130069668A (ko)	2013-06-26
ES2683316T3 (es)	2018-09-26

Publication	Publication Date	Title
ZA201208837B (en)	2013-08-28	Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
ZA201307844B (en)	2015-12-23	Influenza nucleic acid molecules and vaccines made therefrom
IL223206A0 (en)	2013-02-03	Vaccine formulations
GB201005005D0 (en)	2010-05-12	New vaccine
ZA201204050B (en)	2013-02-27	Vaccination syringe
EP2563426A4 (en)	2014-06-18	APPLICATION WITH HIGH SCAM FOR MEDICAL THERAPY
PL2796150T3 (pl)	2021-08-30	Nowe koniugaty oligonukleotydowe i ich zastosowanie
IL237865B (en)	2021-04-29	Compositions of naturally occurring cpg oligonucleotides and their medical applications
EP2654872A4 (en)	2014-05-07	AUTODILATION CANNULA
GB201003293D0 (en)	2010-04-14	Cancer vaccine
GB201014965D0 (en)	2010-10-20	Vaccine
PL2750645T3 (pl)	2018-04-30	Medyczna pończocha podpierająca i uciskowa
EP2558506A4 (en)	2013-08-14	GEWEBEANZIELUNG
SI2536400T1 (sl)	2015-01-30	Zdravilo, ki vsebuje miramistin
PL3097920T3 (pl)	2020-03-31	Kompozycja medyczna zawierająca ekstrakt stauntonia hexaphylla
GB201013006D0 (en)	2010-09-15	Vaccine
GB201006324D0 (en)	2010-06-02	Vaccine
EP2609539A4 (en)	2015-07-15	VIRTUAL HOT CONNECTION TECHNIQUES
ZA201302154B (en)	2014-08-27	Vaccine
GB201012283D0 (en)	2010-09-08	Vaccine
GB201007588D0 (en)	2010-06-23	Vaccine
GB201007589D0 (en)	2010-06-23	Vaccine
GB201009277D0 (en)	2010-07-21	Novel vaccine
GB201008795D0 (en)	2010-07-14	Vaccines
GB201008786D0 (en)	2010-07-14	Vaccines